US 11,912,678 B2
LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases
Ana Martinez Gil, Madrid (ES); Carmen Gil Ayuso-Gontan, Madrid (ES); Josefa Zaldivar Diaz De Bonilla, Madrid (ES); and Rocio Benitez Fernandez, Madrid (ES)
Assigned to CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, Madrid (ES)
Appl. No. 17/270,236
Filed by CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, Madrid (ES)
PCT Filed Aug. 8, 2019, PCT No. PCT/ES2019/070557
§ 371(c)(1), (2) Date Feb. 22, 2021,
PCT Pub. No. WO2020/039110, PCT Pub. Date Feb. 27, 2020.
Claims priority of application No. ES201830841 (ES), filed on Aug. 24, 2018.
Prior Publication US 2021/0323936 A1, Oct. 21, 2021
Int. Cl. C07D 277/80 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01)
CPC C07D 277/80 (2013.01) [A61K 45/06 (2013.01); A61P 25/28 (2018.01)] 14 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
wherein R1 is selected from H, C1-C6 alkyl, halogen, CF3 and —O—C1-C6 alkyl.